FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979384469> ?p ?o ?g. }

• W2979384469 abstract "Abstract Abstract 1504 Background: Induction therapy for non-HIV, primary CNS lymphoma is centered on high-dose methotrexate (MTX) as the most effective chemotherapeutic agent. Combined modality therapy (CMT) using high-dose MTX and whole brain radiotherapy (WBRT) has improved response rates compared to chemotherapy alone. The trade-off is a significant risk of delayed, treatment-related neurotoxicity (NT), leading to significant morbidity and mortality. This risk of NT is greater in patients over the age of 60. As data from randomized controlled trials is not available and it is unlikely to be generated in the future, we performed a decision analysis to explore the implications of the trade-off between improved tumor control with CMT, and decreased NT with chemotherapy. Our analyses compared life expectancy and quality-adjusted life expectancy with these two strategies. Methods: We developed a Markov decision-analytic model to compare CMT versus chemotherapy alone for a hypothetical cohort of 60 year old patients newly-diagnosed with primary CNS lymphoma. The model simulates the clinical course of patients over a 5 year time horizon, with the end-points of life expectancy and quality-adjusted life expectancy. The baseline probabilities used in the model were derived from a systematic review of published studies. Key variables included response, relapse and survival rates with CMT versus chemotherapy alone, risk of developing NT with each strategy, including severe NT, and the estimated survival once NT develops. The model incorporated data on health state utilities, which were derived from a survey of expert physicians who treat patients with primary CNS lymphoma. All patients who received chemotherapy alone as induction therapy were assumed to have received salvage radiotherapy upon relapse. The utility of having active disease was assumed to overcome any ill effects from neurotoxicity. Sensitivity analyses were performed for key variables. Results: The life expectancy was 2.96 years for the CMT strategy and 2.82 years for the chemotherapy alone strategy (with deferred salvage radiotherapy). This yielded a net benefit of 0.14 years for the CMT strategy. The quality-adjusted life expectancies for the two strategies were 2.01 and 1.73 quality-adjusted life years (QALYs), with an expected benefit from CMT as induction therapy of 0.28 QALYs. Sensitivity analysis demonstrated that the model was robust to key variables. The model favoured treating patients with CMT unless the hazard ratio (HR) of time to first relapse with chemotherapy alone versus CMT was <1.02, a lower HR than reported in the literature (base case assumption HR: 2.12). The model was robust to the plausible ranges in probability of developing NT (base probability: 0.18 at 1yr). It favoured treating patients with CMT unless the rate of neurotoxicity was more than 73% at 1yr, a rate not encountered in the published literature. On microsimulation (100 000 trials), 85% of the simulations showed that CMT was the preferred strategy compared to chemotherapy alone. Conclusion: The preferred induction strategy for patients with primary CNS lymphoma appears to be CMT. This strategy maximizes life expectancy, and quality adjusted life years. The model was robust to sensitivity analyses of key variables tested through the plausible ranges obtained from the published literature. Disclosures: No relevant conflicts of interest to declare." @default.
• W2979384469 created "2019-10-18" @default.
• W2979384469 creator A5008282524 @default.
• W2979384469 creator A5024269299 @default.
• W2979384469 creator A5026467222 @default.
• W2979384469 creator A5070115729 @default.
• W2979384469 date "2010-11-19" @default.
• W2979384469 modified "2023-09-28" @default.
• W2979384469 title "Combined Modality Therapy Versus Chemotherapy Alone as An Induction Regimen for Primary CNS Lymphoma: a Decision Analysis." @default.
• W2979384469 doi "https://doi.org/10.1182/blood.v116.21.1504.1504" @default.
• W2979384469 hasPublicationYear "2010" @default.
• W2979384469 type Work @default.
• W2979384469 sameAs 2979384469 @default.
• W2979384469 citedByCount "0" @default.
• W2979384469 crossrefType "journal-article" @default.
• W2979384469 hasAuthorship W2979384469A5008282524 @default.
• W2979384469 hasAuthorship W2979384469A5024269299 @default.
• W2979384469 hasAuthorship W2979384469A5026467222 @default.
• W2979384469 hasAuthorship W2979384469A5070115729 @default.
• W2979384469 hasConcept C126322002 @default.
• W2979384469 hasConcept C133925201 @default.
• W2979384469 hasConcept C141071460 @default.
• W2979384469 hasConcept C143998085 @default.
• W2979384469 hasConcept C207103383 @default.
• W2979384469 hasConcept C2776694085 @default.
• W2979384469 hasConcept C2778041864 @default.
• W2979384469 hasConcept C2778336483 @default.
• W2979384469 hasConcept C2781413609 @default.
• W2979384469 hasConcept C2908647359 @default.
• W2979384469 hasConcept C44249647 @default.
• W2979384469 hasConcept C71924100 @default.
• W2979384469 hasConcept C99454951 @default.
• W2979384469 hasConceptScore W2979384469C126322002 @default.
• W2979384469 hasConceptScore W2979384469C133925201 @default.
• W2979384469 hasConceptScore W2979384469C141071460 @default.
• W2979384469 hasConceptScore W2979384469C143998085 @default.
• W2979384469 hasConceptScore W2979384469C207103383 @default.
• W2979384469 hasConceptScore W2979384469C2776694085 @default.
• W2979384469 hasConceptScore W2979384469C2778041864 @default.
• W2979384469 hasConceptScore W2979384469C2778336483 @default.
• W2979384469 hasConceptScore W2979384469C2781413609 @default.
• W2979384469 hasConceptScore W2979384469C2908647359 @default.
• W2979384469 hasConceptScore W2979384469C44249647 @default.
• W2979384469 hasConceptScore W2979384469C71924100 @default.
• W2979384469 hasConceptScore W2979384469C99454951 @default.
• W2979384469 hasLocation W29793844691 @default.
• W2979384469 hasOpenAccess W2979384469 @default.
• W2979384469 hasPrimaryLocation W29793844691 @default.
• W2979384469 hasRelatedWork W1500477185 @default.
• W2979384469 hasRelatedWork W1593344049 @default.
• W2979384469 hasRelatedWork W1944039537 @default.
• W2979384469 hasRelatedWork W1976105963 @default.
• W2979384469 hasRelatedWork W2014570495 @default.
• W2979384469 hasRelatedWork W2020515796 @default.
• W2979384469 hasRelatedWork W2026783022 @default.
• W2979384469 hasRelatedWork W2026863359 @default.
• W2979384469 hasRelatedWork W2033244705 @default.
• W2979384469 hasRelatedWork W2171412268 @default.
• W2979384469 hasRelatedWork W2559916272 @default.
• W2979384469 hasRelatedWork W2560496039 @default.
• W2979384469 hasRelatedWork W2608960441 @default.
• W2979384469 hasRelatedWork W2754738893 @default.
• W2979384469 hasRelatedWork W2756060398 @default.
• W2979384469 hasRelatedWork W2760837506 @default.
• W2979384469 hasRelatedWork W2901927271 @default.
• W2979384469 hasRelatedWork W2906940684 @default.
• W2979384469 hasRelatedWork W3189232472 @default.
• W2979384469 hasRelatedWork W3209852416 @default.
• W2979384469 isParatext "false" @default.
• W2979384469 isRetracted "false" @default.
• W2979384469 magId "2979384469" @default.
• W2979384469 workType "article" @default.